A Case of Bladder Large Cell Carcinoma with Review of the Literature

Overview

Journal Case Rep Oncol

Publisher Karger

Specialty Oncology

Date 2022 May 9

PMID 35529284

Authors

Paolo Lopedote

Amir Yosef

Olga Kozyreva

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine (NE) tumors of the bladder are infrequent. Among them, large cell NE tumor has been outlined only in case reports and short case series, which describes them as aggressive malignancies with dismal prognosis requiring a multidisciplinary approach. The case of an 82-year-old patient with muscle-invasive large cell NE carcinoma of the bladder associated with urothelial carcinoma in situ is presented. Despite combined treatment modality, relapse with metastatic disease was detected 12.5 months after the initial diagnosis. Thereafter, we review several published cases, and results of the collected data are compared with the largest studies published on this topic.

Citing Articles

Large-cell neuroendocrine carcinoma of the bladder: A case report.

Zhou Y, Yang L World J Clin Oncol. 2024; 15(9):1239-1244.

PMID: 39351458 PMC: 11438854. DOI: 10.5306/wjco.v15.i9.1239.

Unusual Association of Large Cell Neuroendocrine Carcinoma of the Bladder and Prostatic Adenocarcinoma Within a 76-Year-Old Man.

Nassira K, Aberkane M, El Moudane A, Haloui A, Bennani A Cureus. 2024; 16(8):e67651.

PMID: 39314614 PMC: 11417971. DOI: 10.7759/cureus.67651.

Primary pure large cell neuroendocrine carcinoma of the urinary bladder: a case report and literature review.

Sun Z, Liang X, Zhang C, Song S, Gao J Front Oncol. 2024; 14:1337997.

PMID: 38529382 PMC: 10961446. DOI: 10.3389/fonc.2024.1337997.

References

Zhou H, Liu L, Yu G, Qu G, Gong P, Yu X . Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma. Anticancer Res. 2017; 37(8):4529-4537. DOI: 10.21873/anticanres.11850. View

Le Treut J, Sault M, Lena H, Souquet P, Vergnenegre A, Le Caer H . Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013; 24(6):1548-52. DOI: 10.1093/annonc/mdt009. View

Evans A, Humphrey P, Belani J, van der Kwast T, Srigley J . Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006; 30(6):684-93. DOI: 10.1097/00000478-200606000-00003. View

Engles C, Slobodov G, Buethe D, Lightfoot S, Culkin D . Primary mixed neuroendocrine carcinoma of the bladder with large cell component: a case report and review of the literature. Int Urol Nephrol. 2012; 44(4):1021-5. DOI: 10.1007/s11255-012-0148-6. View

Tlili G, Ammar H, Majdoub W, Dziri S, Farhat W, Acacha E . Paraplegia due to medullary compression caused by a large cell neuroendocrine carcinoma of the urinary bladder: A case report. Ann Med Surg (Lond). 2021; 67:102475. PMC: 8220165. DOI: 10.1016/j.amsu.2021.102475. View

Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Moricke A . Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 2013; 121(26):5145-53. DOI: 10.1182/blood-2013-01-480335. View

Sroussi M, Elaidi R, Flechon A, Lorcet M, Borchiellini D, Tardy M . Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. Clin Genitourin Cancer. 2019; 18(4):295-303.e3. DOI: 10.1016/j.clgc.2019.11.014. View

Treglia G, Paone G, Flores B, Venzi G, Ceriani L, Giovanella L . A rare case of large cell neuroendocrine carcinoma of the urinary bladder evaluated by ¹⁸F-FDG-PET/CT. Rev Esp Med Nucl Imagen Mol. 2014; 33(5):312-3. DOI: 10.1016/j.remn.2013.10.007. View

Lee W, Kim C, Chang S, Lee M, Choi J, Moon K . Cutaneous metastasis from large-cell neuroendocrine carcinoma of the urinary bladder expressing CK20 and TTF-1. Am J Dermatopathol. 2009; 31(2):166-9. DOI: 10.1097/DAD.0b013e31818eba4c. View

10.

Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M . Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013; 8(7):980-4. DOI: 10.1097/JTO.0b013e31828f6989. View

11.

Hatayama T, Hayashi T, Matsuzaki S, Masumoto H, Yanai H, Abdi H . Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab. IJU Case Rep. 2020; 3(6):252-256. PMC: 7609171. DOI: 10.1002/iju5.12208. View

12.

Liu S, Reck M, Mansfield A, Mok T, Scherpereel A, Reinmuth N . Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021; 39(6):619-630. PMC: 8078320. DOI: 10.1200/JCO.20.01055. View

13.

Canbey Goret C . Neuroendocrine tumors of the urinary bladder A case series and review of the literature. Ann Ital Chir. 2020; 91:65-68. View

14.

Wang G, Yuan R, Zhou C, Guo C, Villamil C, Hayes M . Urinary Large Cell Neuroendocrine Carcinoma: A Clinicopathologic Analysis of 22 Cases. Am J Surg Pathol. 2021; 45(10):1399-1408. PMC: 8428850. DOI: 10.1097/PAS.0000000000001740. View

15.

Sherman S, Rotem O, Shochat T, Zer A, Moore A, Dudnik E . Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer. 2020; 143:40-46. DOI: 10.1016/j.lungcan.2020.03.008. View

16.

Moretto P, Wood L, Emmenegger U, Blais N, Mukherjee S, Winquist E . Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Can Urol Assoc J. 2013; 7(1-2):E44-56. PMC: 3650822. DOI: 10.5489/cuaj.220. View

17.

Nguyen O, Sundstrom S, Westvik G, Rottereng A, Melhus M, Bergseth C . Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report. Case Rep Oncol. 2020; 13(3):1059-1066. PMC: 7548951. DOI: 10.1159/000509747. View

18.

Amin M . Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009; 22 Suppl 2:S96-S118. DOI: 10.1038/modpathol.2009.26. View

19.

Rossi A, Di Maio M, Chiodini P, Rudd R, Okamoto H, Skarlos D . Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012; 30(14):1692-8. DOI: 10.1200/JCO.2011.40.4905. View

20.

Oshiro H, Gomi K, Nagahama K, Nagashima Y, Kanazawa M, Kato J . Urinary cytologic features of primary large cell neuroendocrine carcinoma of the urinary bladder: a case report. Acta Cytol. 2010; 54(3):303-10. DOI: 10.1159/000325039. View